LEPR and Alzheimer disease: For example, the SGLT2i Empagliflozin reportedly reduced beta‐amyloid levels and improved cognitive abilities in a murine model of Alzheimer's disease (AD) crossed to the diabetes model of leptin receptor deficiency (db/db), or in db/db mice alone (Hierro‐Bujalance et al., 2020), (Lin et al., 2014).